Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer-Results from Phase Ib Trial IMU.ACS.001.

Ursula WiedermannErika Garner-SpitzerYee ChaoMarina MaglakelidzeIurie BulatArunee DechaphunkulWichit ArpornwiratChaiyut CharoentumChia-Jui YenThomas Cheung YauSuebpong TanasanvimonJedzada ManeechavakajornAumkhae SookprasertLi-Yuan BaiWen-Chi ChouTeerapat UngtrakulMirjana DrinicJoshua TobiasChristoph C ZielinskiLeslie ChongNicholas J EdeMark T MarinoAnthony J Good

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

IMU-131 was well tolerated and safe. The induced HER2-specific Abs and cellular responses were dose dependent and correlated with clinical responses. The highest dose (50 μg) was recommended for further evaluation in a phase II trial, with chemotherapy + IMU-131 or chemotherapy alone, which is currently ongoing.

Keyphrases

locally advanced
acute coronary syndrome
neoadjuvant chemotherapy
clinical trial
study protocol
randomized controlled trial
endothelial cells
rectal cancer
placebo controlled
double blind